Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases

Maurya, Sujata and Srivastava, Rashi and Arfin, Saniya and Hawthorne, Susan and Jha, Niraj Kumar and Agrawal, Kirti and Raj, Sibi and Rathi, Brijesh and Kumar, Arun and Raj, Riya and Agrawal, Sharad and Paiva-Santos, Ana Cláudia and Malik, Asrar Ahmad and Dua, Kamal and Rana, Rakesh and Ojha, Shreesh and Jha, Saurabh Kumar and Sharma, Ankur and Kumar, Dhruv and El-Zahaby, Sally A and Nagar, Amka (2023) Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases. Nanomedicine, 17 (30). pp. 2245-2264. ISSN 1743-5889 (https://doi.org/10.2217/nnm-2021-0437)

[thumbnail of Maurya-etal-Nanomedicine-2023-Exploring-state-of-the-art-advances-in-targeted-nanomedicines-for-managing-acute-and-chronic-inflammatory-lung-diseases]
Preview
 Text. Filename: Maurya_etal_Nanomedicine_2023_Exploring_state_of_the_art_advances_in_targeted_nanomedicines_for_managing_acute_and_chronic_inflammatory_lung_diseases.pdf
Accepted Author Manuscript
License: Strathprints license 1.0
Download (1MB)| Preview

Abstract

Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.

CORE (COnnecting REpositories)